Navigation Links
Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research
Date:10/19/2007

A new partnership to build an integrated neuroscience research programme that spans basic science all the way to clinical research. Strategic research infrastructure for tertiary hospitals and medical schools, and a national organisation to support and strengthen late phase clinical trials in Singapore. These are some of the new initiatives that were endorsed by the Biomedical Sciences International Advisory Council (BMS IAC) at their annual meeting today. These initiatives will boost Singapores translational and clinical research (TCR) capabilities which is the focus of our Biomedical Sciences (BMS) Initiative Phase 2.

This years BMS IAC meeting was the 12th since the Council was formed in 2000. It was chaired by Sir Richard Sykes, Rector Imperial College London, and was attended by 9 eminent scientists from the US, UK, Europe, Canada and Australia.

The IAC members commended the progress that has been made over the past one year since the launch of Phase 2 of the BMS initiative by the Biomedical Sciences Executive Committee (BMS EXCO), which is co-chaired by Mr Lim Chuan Poh, Chairman of the Agency for Science, Technology and Research (A*STAR), and Ms Yong Ying-I, Permanent Secretary of the Ministry of Health (MOH).

Neuroscience Research Partnership forged between A*STAR and Duke- NUS Graduate Medical School

The BMS IAC was supportive of the partnership between A*STAR and the Duke-NUS Graduate Medical School (GMS) to develop an integrated multidisciplinary neuroscience research programme with a strong focus on translational research. They noted that the Neuroscience Research Partnership will capitalise on the complementary research strengths and resources within the A*STAR research institutes and consortia and the Signature Research Programme on Neurobehavioural Disorders at Duke-NUS GMS.

Neuroscience has been identified as one of five disease areas of research priority to Singapore. The A*STAR Duk
'/>"/>

Contact: Janet Low
janet_low@a-star.edu.sg
656-826-6337
Agency for Science, Technology and Research (A*STAR), Singapore
Source:Eurekalert

Page: 1 2 3 4 5 6

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Worlds largest rainforest drying experiment completes first phase
3. Kinovate Life Sciences Launches Nittophase?High Performance Solid Support For Oligonucleatide Synthesis
4. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
5. Eisai announces Phase II data on E7389, a potential new therapy for the treatment of breast cancer
6. Ebola DNA vaccine produces immune responses in all fully vaccinated volunteers in Phase 1 trial
7. NIH announces phase III clinical trial of creatine for Parkinsons disease
8. Automatic extraction of gene/protein biological functions from biomedical text
9. Breakthrough method in nanoparticle synthesis paves the way for new pharmaceutical and biomedical applications
10. Scientists create digital bacteria to forge advances in biomedical research
11. Boston University biomedical engineers win major grant for pursuit of the $1,000 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/15/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... mobile commerce market, announces that its leading payment security technology, ... Digital Experience! @ NYC June 18th. Digital Experience! ... innovation in technology to over 300 of the top media ... Metropolitan Pavilion in New York City ...
(Date:6/11/2015)... RESTON, Va. , June 11, 2015 /PRNewswire/ ... authentication technology, announced today that its IdentityX Mobile ... FIDO (Fast IDentity Online) Alliance is an industry ... with open standards for simpler, stronger authentication.  In ... services must pass a rigorous series of tests ...
(Date:6/9/2015)... 2015   MedNet Solutions , an innovative SaaS-based ... clinical research, will be providing demonstrations of its ... 2015 Drug Information Association (DIA) Annual Meeting in ... presentations will include previews of many exciting new enhancements ... iMedNet 2015 Feature 1 Release. ...
Breaking Biology News(10 mins):Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3
... risk of death among injection drug users living with ... (ART), according to a new study involving Simon Fraser ... journal, PLoS One , examines the impact of ... users. Food insecurity is defined by the United Nations, ...
... sensitive ears of a parasitic fly for inspiration, a ... microphone that achieves better acoustical performance than what is ... their results at the 21st International Congress on Acoustics, ... Distinguished Professor of Mechanical Engineering at Binghamton University, studies ...
... at the MRC Laboratory of Molecular Biology in the United ... found in cells that when mutated can lead to a ... in The EMBO Journal , define the position of ... explain how these alterations may affect the stability and function ...
Cached Biology News:Food insecurity linked to HIV-treated drug users' deaths 2Researchers design sensitive new microphone modeled on fly ear 2How disease mutations affect the Parkin protein 2
(Date:6/30/2015)... SAN DIEGO , June 30, 2015 /PRNewswire/ ... Continuing Education in Biosciences (CCE/Bio) and UC San ... microbial fermentation, to be held Aug.  12 – ... agenda ).  This three-day workshop provides an intense ... in industrial biotechnology, and is well-suited to biologists, ...
(Date:6/30/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... on the development of autologous cell therapies, announced today ... clinical trial of RCT-01, being tested for the ... enrolled and their tissue biopsy sent for processing ... of non-bulbar dermal sheath (NBDS) cells isolated from ...
(Date:6/30/2015)... Edwardsville, IL (PRWEB) , ... June 30, 2015 ... ... resigned effective August 14. She has accepted the position of vice president of ... on August 17. , “I greatly appreciated the opportunity to lead SIUE ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by filmmakers, the ... dynamic collection of legal medical cannabis stories ever assembled. , Cannavoices profiles ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3
... Feb. 26 One of,Brazil,s leading distributors of pharmaceutical products, ... has just announced its results for the fourth quarter of,2007 ... PERIOD, -- Profarma,s market share breaks record and reaches ... above the share reached in the 3Q07 and 3.2 ...
... 8: ,Venous Thromboembolism and Mortality Associated with Recombinant ... the Treatment of Cancer-Associated Anemia, BRIDGEWATER, N.J., Feb. ... study published in the February 27, 2008 issue of ... et al, do,not provide an accurate reflection of the ...
... ALTO, Calif., Feb. 26 CV Therapeutics,Inc. (Nasdaq: CVTX ... year ended December 31, 2007., For the quarter ended ... million, or $0.57 per share. This compares to a net ... quarter in 2006 and $34.2,million, or $0.58 per share, for ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 2CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 3CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 4CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 5CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 6CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 7CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results 8
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
PI/RNase Staining Buffer Solution , 100 ml Consult technical datasheet for details....
Oct 2 Immunogen: Full length human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: